Shares of Heska Corporation (NASDAQ:HSKA) have been assigned an average recommendation of “Hold” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $114.38.

HSKA has been the subject of a number of recent analyst reports. B. Riley dropped their price target on shares of Heska from $96.50 to $93.00 and set a “neutral” rating for the company in a research report on Friday, November 3rd. Zacks Investment Research upgraded shares of Heska from a “hold” rating to a “buy” rating and set a $109.00 price target for the company in a research report on Friday, August 4th. Benchmark reissued a “buy” rating and issued a $120.00 target price (up previously from $106.00) on shares of Heska in a report on Wednesday, August 9th. BidaskClub raised shares of Heska from a “hold” rating to a “buy” rating in a report on Thursday, August 3rd. Finally, Canaccord Genuity assumed coverage on shares of Heska in a report on Thursday, October 5th. They issued a “buy” rating and a $115.00 target price on the stock.

Shares of Heska (NASDAQ:HSKA) traded up $0.48 during midday trading on Friday, reaching $86.31. 70,273 shares of the company traded hands, compared to its average volume of 82,340. The company has a market capitalization of $628.11, a price-to-earnings ratio of 45.40, a price-to-earnings-growth ratio of 2.31 and a beta of 0.83. Heska has a 12 month low of $64.52 and a 12 month high of $115.00.

Heska (NASDAQ:HSKA) last posted its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.03. The business had revenue of $31.40 million during the quarter, compared to analyst estimates of $36.10 million. Heska had a net margin of 10.67% and a return on equity of 15.35%. The company’s revenue was down 6.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.45 earnings per share. analysts forecast that Heska will post 2.03 EPS for the current fiscal year.

In other news, insider Michael J. Mcginley sold 7,826 shares of the business’s stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total value of $681,957.64. Following the transaction, the insider now owns 106,771 shares of the company’s stock, valued at $9,304,024.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 14.70% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Neuberger Berman Group LLC raised its stake in Heska by 34.2% during the third quarter. Neuberger Berman Group LLC now owns 603,469 shares of the medical research company’s stock valued at $53,160,000 after purchasing an additional 153,895 shares in the last quarter. Vanguard Group Inc. raised its stake in Heska by 31.7% during the second quarter. Vanguard Group Inc. now owns 461,841 shares of the medical research company’s stock valued at $47,141,000 after purchasing an additional 111,232 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Heska by 18.1% during the second quarter. Russell Investments Group Ltd. now owns 225,388 shares of the medical research company’s stock valued at $23,005,000 after purchasing an additional 34,594 shares in the last quarter. State Street Corp raised its stake in Heska by 12.7% during the second quarter. State Street Corp now owns 195,970 shares of the medical research company’s stock valued at $19,998,000 after purchasing an additional 22,053 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Heska by 26.0% during the third quarter. Dimensional Fund Advisors LP now owns 151,460 shares of the medical research company’s stock valued at $13,342,000 after purchasing an additional 31,286 shares in the last quarter. 81.98% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Heska Corporation (HSKA) Receives Average Recommendation of “Hold” from Brokerages” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/01/heska-corporation-hska-receives-average-recommendation-of-hold-from-brokerages.html.

Heska Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.